Watch RNAC. Know when insiders buy.
One email the day a filing lands. Free.
RNAC
Cartesian Therapeutics, Inc.
7.41
−0.21 −2.76%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $224.2MP/E —DIV YIELD —FCF YIELD -35.06%REV TTM $1.5M +44.0%NET INCOME −$151.9MNET CASH $94.8M52W 5.84 – 10.59SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$29.2M | $15.8M | −0.7% | 0.46 | −$21.1M | $272K | −$21.4M | Aug 6 |
| Q1 2026 · Mar 31 | $78K | −92.9% | — | −$26.5M | −$39.2M | — | -1.46 | −$22.1M | $27K | −$22.2M | Aug 6 |
| Q4 2025 · Dec 31derived | $947K | — | — | −$78.6M | −$92.6M | — | -3.57 | −$17.7M | $492K | −$18.2M | Mar 9 |
| Q3 2025 · Sep 30 | $452K | +16.8% | — | −$21.1M | −$35.9M | — | -1.38 | −$15.6M | $1.3M | −$16.9M | Nov 6 |
| Q2 2025 · Jun 30 | $298K | −99.1% | — | −$21.8M | $15.9M | +14.8% | 0.50 | −$17.5M | $2.6M | −$20.1M | Aug 6 |
| Q1 2025 · Mar 31 | $1.1M | −81.2% | — | −$21.9M | −$17.7M | — | -0.68 | −$23.1M | $1.1M | −$24.2M | Aug 6 |
| Q4 2024 · Dec 31derived | −$759K | −109.2% | — | −$26.7M | −$10.3M | — | 0.12 | −$7M | $705K | −$7.7M | Mar 9 |
| Q3 2024 · Sep 30 | $387K | −94.1% | — | −$17.6M | −$24.2M | — | -1.13 | $13.7M | $6.2M | $7.5M | Nov 6 |
| Q2 2024 · Jun 30 | $33.4M | — | — | $13.8M | $13.8M | — | 0.54 | −$14.4M | $1.6M | −$16M | Nov 6 |
| Q1 2024 · Mar 31 | $5.8M | — | — | −$13.3M | −$56.8M | — | -10.50 | −$15.9M | $602K | −$16.5M | Nov 6 |
| Q4 2023 · Dec 31derived | $8.3M | — | — | −$36.3M | −$177.7M | — | -41.56 | −$23.3M | $64K | −$23.4M | Mar 13 |
| Q3 2023 · Sep 30 | $6.6M | — | — | −$13.1M | −$9M | — | -1.74 | −$9.2M | $0 | −$9.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.8M | — | −$143.4M | −$130.3M | -4658.6% | -5.02 | −$73.9M | $5.5M | −$79.4M | — | — |
| FY2024 · to Dec 31 | $38.9M | — | −$43.9M | −$77.4M | -199.0% | -4.49 | −$23.7M | $9.1M | −$32.8M | — | — |
| FY2023 · to Dec 31 | $26M | — | −$86.4M | −$219.7M | -844.9% | -49.76 | −$51.2M | $206K | −$51.4M | — | — |
| FY2022 · to Dec 31 | $110.8M | — | $14.5M | $35.4M | 31.9% | 0.10 | −$31.6M | $1.2M | −$32.8M | — | — |
| FY2021 · to Dec 31 | $85.1M | — | −$4.6M | −$25.7M | -30.2% | -0.22 | −$60.4M | $1.1M | −$61.5M | — | — |
| FY2020 · to Dec 31 | $16.6M | — | −$56.8M | −$68.9M | -415.0% | -0.68 | $34.9M | $815K | $34.1M | — | — |
Every number comes from Cartesian Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.